5 Of The Best-Performing Biotech Stocks Of 2017

Sangamo Therapeutics, Inc. (SGMO - Free Report) : Clinical-stage biotech company, Sangamo, is focused on translating ground-breaking science into genomic therapies using its platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company got a shot in the arm earlier this year when it entered into an agreement with Pfizer (PFE - Free Report) for the development and commercialization of gene therapy programs for hemophilia A. The agreement saw Sangamo getting an upfront payment of $70 million with the potential to earn significant milestone payments as well as tiered double-digit royalties on net sales. This deal bodes well for the long-term prospects of the company. The Zacks Rank #2 (Buy) company’s shares are up 468.9% year to date.

Early next year, Sangamo expects preliminary proof-of-concept data on SB-525 (hemophilia A), SB-FIX (hemophilia B), SB-318 (MPS I) and SB-319 (MPS II). Other value drivers could be the signing of partnership deals for the company’s central nervous system/tau and oncology assets.

Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) : RNAi therapeutics company, Alnylam, is focused on rare genetic, cardio-metabolic, and hepatic infectious diseases. The Zacks Rank #3 company has a strong discovery platform and a deep pipeline including four pipeline candidates that are in late-stage development. Alnylam has agreements with companies like Sanofi and Vir Biotechnology. Alnylam’s shares are up 243.4% year to date on the back of pipeline progress during the year.

bluebird bio, Inc. (BLUE - Free Report) : bluebird is a clinical-stage company working on developing lentiviral-based gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer. The company’s pipeline includes Lenti-D, currently in a phase II/III study, for the treatment of cerebral adrenoleukodystrophy, and LentiGlobin, currently in five studies for the treatment of transfusion-dependent β-thalassemia and severe sickle cell disease. The company’s lead oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs which are being developed in collaboration with Celgene.

View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.